Zhisen Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Zhisen Zhang has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- Lei Chang
State Key Laboratory of Radiation Medicine and Protection, Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, Jiangsu Key Laboratory of Infection and Immunity, The Fourth Affiliated Hospital of Soochow University, School of Radiation Medicine and Protection, Suzhou Medical College of Soochow University, Suzhou 215123, China; Institute of Radiation Medicine, Shanghai Medical College, Fudan University, Shanghai 200032, China
11 shared publications - Yinyin Shu
Institute of Radiation Medicine, Shanghai Medical College, Fudan University, Shanghai 200032, China
10 shared publications - Shuai Dong
State Key Laboratory of Radiation Medicine and Protection, School of Radiation Medicine and Protection, Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, Medical College of Soochow University, Suzhou, China
9 shared publications - Haisheng Liang
Institute of Radiation Medicine, Shanghai Medical College, Fudan University, Shanghai 200032, China
8 shared publications - Lingchuan Guo
Department of Pathology the First Affiliated Hospital of Soochow University Suzhou China
8 shared publications - Mintao Ji
Institute of Radiation Medicine, Shanghai Medical College, Fudan University, Shanghai 200032, China
8 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Ku70 Binding to YAP Alters PARP1 Ubiquitination to Regulate Genome Stability and Tumorigenesis
Figure S1, Figure S2, Figure S3, Figure S4, Figure S5, Figure S6, Figure S7, Figure S8
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Ku70 Binding to YAP Alters PARP1 Ubiquitination to Regulate Genome Stability and Tumorigenesis
Figure S1, Figure S2, Figure S3, Figure S4, Figure S5, Figure S6, Figure S7, Figure S8
- 2 April 2026
- Published by Elsevier in Journal of Hepatology
- Vol. 85  (2) , 212-226
Chromatin remodeling in pericentral hepatocytes modulates MASH through CYP450 activity
- 2 April 2026
- Published by Elsevier in Journal of Hepatology
- Vol. 85  (2) , 212-226
Chromatin remodeling in pericentral hepatocytes modulates MASH through CYP450 activity
- Open Access
- 17 November 2025
- Published by Springer Nature in Cell Death & Disease
- Vol. 16  (1) , 840
PABPC3 drives ovarian cancer metastasis and drug sensitivity by downregulating CLDN1 expression
Ovarian cancer remains one of the most lethal malignancies affecting women, with its high mortality rate primarily attributed to the aggressive metastatic nature of the disease, leading to late-stage diagnoses. The challenges posed by tumor metastasis and treatment resistance significantly complicate disease management and substantially reduce survival rates. Thus, elucidating the mechanisms underlying ovarian cancer metastasis is crucial for developing targeted therapies and improving patient outcomes. In this study, through single-nucleus RNA sequencing and analysis of clinical samples, we identify PABPC3 as a key regulator of ovarian cancer metastasis and patient survival. Functional experiments reveal that PABPC3 knockdown markedly inhibits ovarian cancer cell proliferation and migration, whereas its overexpression exerts the opposite effects. Furthermore, in vivo models confirm that PABPC3 overexpression significantly enhances metastatic potential. Mechanistically, PABPC3 promotes tumor metastasis by modulating the expression of CLDN1, a critical component of tight junctions. PABPC3 knockdown leads to a significant upregulation of CLDN1, while simultaneous CLDN1 knockdown partially rescues the migration-inhibitory effects induced by PABPC3 depletion. Additionally, clinical analyses demonstrate that high PABPC3 expression correlates with shorter overall survival, even among patients receiving chemotherapy. Notably, increased PABPC3 protein levels in metastatic lesions are associated with reduced progression-free survival. In conclusion, this study underscores the pivotal role of PABPC3 in ovarian cancer metastasis and patient prognosis, highlighting it as a potential therapeutic target for improving clinical outcomes.
- 17 November 2025
- Published by Springer Nature in Cell Death & Disease
- Vol. 16  (1) , 840
Open AccessPABPC3 drives ovarian cancer metastasis and drug sensitivity by downregulating CLDN1 expression
Ovarian cancer remains one of the most lethal malignancies affecting women, with its high mortality rate primarily attributed to the aggressive metastatic nature of the disease, leading to late-stage diagnoses. The challenges posed by tumor metastasis and treatment resistance significantly complicate disease management and substantially reduce survival rates. Thus, elucidating the mechanisms underlying ovarian cancer metastasis is crucial for developing targeted therapies and improving patient outcomes. In this study, through single-nucleus RNA sequencing and analysis of clinical samples, we identify PABPC3 as a key regulator of ovarian cancer metastasis and patient survival. Functional experiments reveal that PABPC3 knockdown markedly inhibits ovarian cancer cell proliferation and migration, whereas its overexpression exerts the opposite effects. Furthermore, in vivo models confirm that PABPC3 overexpression significantly enhances metastatic potential. Mechanistically, PABPC3 promotes tumor metastasis by modulating the expression of CLDN1, a critical component of tight junctions. PABPC3 knockdown leads to a significant upregulation of CLDN1, while simultaneous CLDN1 knockdown partially rescues the migration-inhibitory effects induced by PABPC3 depletion. Additionally, clinical analyses demonstrate that high PABPC3 expression correlates with shorter overall survival, even among patients receiving chemotherapy. Notably, increased PABPC3 protein levels in metastatic lesions are associated with reduced progression-free survival. In conclusion, this study underscores the pivotal role of PABPC3 in ovarian cancer metastasis and patient prognosis, highlighting it as a potential therapeutic target for improving clinical outcomes.
- Open Access
- 12 November 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122  (46)
The SWI/SNF chromatin-remodeling subunit DPF2 regulates macrophage inflammation in intestinal injury via the CACNA1D-mediated MAPK pathway
The immune system plays a pivotal role in pathogenesis of intestinal injury and subsequent regenerative processes, particularly macrophages, orchestrate the inflammatory response and tissue repair. Here, we identified that loss of double PHD fingers 2 (DPF2) enhances intestinal regeneration and reduces inflammation. Using a combination of mouse genetics, single cell RNA sequencing, and spatial transcriptomics, we found that Dpf2 loss in macrophage modulates inflammatory polarization, thus protecting against intestinal injury. Mechanistically, Dpf2 deficiency leads to loss of H3K27ac and H3K4me1 marks at Cacna1d enhancer, impairing Cacna1d messenger RNA (mRNA) expression and reducing intracellular calcium. Consequently, loss of Dpf2 attenuates mitogen-activated protein kinases signaling activity, promoting an anti-inflammatory macrophage polarization. Finally, through analysis of clinical inflammatory bowel disease (IBD) single cell RNA and spatial transcriptome data, patient-derived organoids and clinical samples, we validated a positive correlation between DPF2, CACNA1D, and intestinal inflammation. Our findings establish an essential role for DPF2 in facilitating CACNA1D expression in macrophages to regulate intestinal inflammation and regeneration.
- 12 November 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122  (46)
Open AccessThe SWI/SNF chromatin-remodeling subunit DPF2 regulates macrophage inflammation in intestinal injury via the CACNA1D-mediated MAPK pathway
The immune system plays a pivotal role in pathogenesis of intestinal injury and subsequent regenerative processes, particularly macrophages, orchestrate the inflammatory response and tissue repair. Here, we identified that loss of double PHD fingers 2 (DPF2) enhances intestinal regeneration and reduces inflammation. Using a combination of mouse genetics, single cell RNA sequencing, and spatial transcriptomics, we found that Dpf2 loss in macrophage modulates inflammatory polarization, thus protecting against intestinal injury. Mechanistically, Dpf2 deficiency leads to loss of H3K27ac and H3K4me1 marks at Cacna1d enhancer, impairing Cacna1d messenger RNA (mRNA) expression and reducing intracellular calcium. Consequently, loss of Dpf2 attenuates mitogen-activated protein kinases signaling activity, promoting an anti-inflammatory macrophage polarization. Finally, through analysis of clinical inflammatory bowel disease (IBD) single cell RNA and spatial transcriptome data, patient-derived organoids and clinical samples, we validated a positive correlation between DPF2, CACNA1D, and intestinal inflammation. Our findings establish an essential role for DPF2 in facilitating CACNA1D expression in macrophages to regulate intestinal inflammation and regeneration.
- Open Access
- 4 September 2024
- Published by American Association for Cancer Research (AACR)
Data from Ku70 Binding to YAP Alters PARP1 Ubiquitination to Regulate Genome Stability and Tumorigenesis
Yes-associated protein (YAP) is a central player in cancer development, with functions extending beyond its recognized role in cell growth regulation. Recent work has identified a link between YAP/transcriptional coactivator with PDZ-binding motif (TAZ) and the DNA damage response. Here, we investigated the mechanistic underpinnings of the cross-talk between DNA damage repair and YAP activity. Ku70, a key component of the nonhomologous end joining pathway to repair DNA damage, engaged in a dynamic competition with TEAD4 for binding to YAP, limiting the transcriptional activity of YAP. Depletion of Ku70 enhanced interaction between YAP and TEAD4 and boosted YAP transcriptional capacity. Consequently, Ku70 loss enhanced tumorigenesis in colon cancer and hepatocellular carcinoma (HCC) in vivo. YAP impeded DNA damage repair and elevated genome instability by inducing PARP1 degradation through the SMURF2-mediated ubiquitin-proteasome pathway. Analysis of samples from patients with HCC substantiated the link between Ku70 expression, YAP activity, PARP1 levels, and genome instability. In conclusion, this research provides insight into the mechanistic interactions between YAP and key regulators of DNA damage repair, highlighting the role of a Ku70-YAP-PARP1 axis in preserving genome stability.Significance: Increased yes-associated protein transcriptional activity stimulated by loss of Ku70 induces PARP1 degradation by upregulating SMURF2 to inhibit DNA damage, driving genome instability and tumorigenesis.
- 4 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Ku70 Binding to YAP Alters PARP1 Ubiquitination to Regulate Genome Stability and Tumorigenesis
Yes-associated protein (YAP) is a central player in cancer development, with functions extending beyond its recognized role in cell growth regulation. Recent work has identified a link between YAP/transcriptional coactivator with PDZ-binding motif (TAZ) and the DNA damage response. Here, we investigated the mechanistic underpinnings of the cross-talk between DNA damage repair and YAP activity. Ku70, a key component of the nonhomologous end joining pathway to repair DNA damage, engaged in a dynamic competition with TEAD4 for binding to YAP, limiting the transcriptional activity of YAP. Depletion of Ku70 enhanced interaction between YAP and TEAD4 and boosted YAP transcriptional capacity. Consequently, Ku70 loss enhanced tumorigenesis in colon cancer and hepatocellular carcinoma (HCC) in vivo. YAP impeded DNA damage repair and elevated genome instability by inducing PARP1 degradation through the SMURF2-mediated ubiquitin-proteasome pathway. Analysis of samples from patients with HCC substantiated the link between Ku70 expression, YAP activity, PARP1 levels, and genome instability. In conclusion, this research provides insight into the mechanistic interactions between YAP and key regulators of DNA damage repair, highlighting the role of a Ku70-YAP-PARP1 axis in preserving genome stability.Significance: Increased yes-associated protein transcriptional activity stimulated by loss of Ku70 induces PARP1 degradation by upregulating SMURF2 to inhibit DNA damage, driving genome instability and tumorigenesis.
- Open Access
- 4 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Ku70 Binding to YAP Alters PARP1 Ubiquitination to Regulate Genome Stability and Tumorigenesis
Figure S1, Figure S2, Figure S3, Figure S4, Figure S5, Figure S6, Figure S7, Figure S8
- 4 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Ku70 Binding to YAP Alters PARP1 Ubiquitination to Regulate Genome Stability and Tumorigenesis
Figure S1, Figure S2, Figure S3, Figure S4, Figure S5, Figure S6, Figure S7, Figure S8
- Open Access
- 4 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Ku70 Binding to YAP Alters PARP1 Ubiquitination to Regulate Genome Stability and Tumorigenesis
Figure S1, Figure S2, Figure S3, Figure S4, Figure S5, Figure S6, Figure S7, Figure S8
- 4 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Ku70 Binding to YAP Alters PARP1 Ubiquitination to Regulate Genome Stability and Tumorigenesis
Figure S1, Figure S2, Figure S3, Figure S4, Figure S5, Figure S6, Figure S7, Figure S8
- Open Access
- 4 September 2024
- Published by American Association for Cancer Research (AACR)
Data from Ku70 Binding to YAP Alters PARP1 Ubiquitination to Regulate Genome Stability and Tumorigenesis
Yes-associated protein (YAP) is a central player in cancer development, with functions extending beyond its recognized role in cell growth regulation. Recent work has identified a link between YAP/transcriptional coactivator with PDZ-binding motif (TAZ) and the DNA damage response. Here, we investigated the mechanistic underpinnings of the cross-talk between DNA damage repair and YAP activity. Ku70, a key component of the nonhomologous end joining pathway to repair DNA damage, engaged in a dynamic competition with TEAD4 for binding to YAP, limiting the transcriptional activity of YAP. Depletion of Ku70 enhanced interaction between YAP and TEAD4 and boosted YAP transcriptional capacity. Consequently, Ku70 loss enhanced tumorigenesis in colon cancer and hepatocellular carcinoma (HCC) in vivo. YAP impeded DNA damage repair and elevated genome instability by inducing PARP1 degradation through the SMURF2-mediated ubiquitin-proteasome pathway. Analysis of samples from patients with HCC substantiated the link between Ku70 expression, YAP activity, PARP1 levels, and genome instability. In conclusion, this research provides insight into the mechanistic interactions between YAP and key regulators of DNA damage repair, highlighting the role of a Ku70-YAP-PARP1 axis in preserving genome stability.Significance: Increased yes-associated protein transcriptional activity stimulated by loss of Ku70 induces PARP1 degradation by upregulating SMURF2 to inhibit DNA damage, driving genome instability and tumorigenesis.
- 4 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Ku70 Binding to YAP Alters PARP1 Ubiquitination to Regulate Genome Stability and Tumorigenesis
Yes-associated protein (YAP) is a central player in cancer development, with functions extending beyond its recognized role in cell growth regulation. Recent work has identified a link between YAP/transcriptional coactivator with PDZ-binding motif (TAZ) and the DNA damage response. Here, we investigated the mechanistic underpinnings of the cross-talk between DNA damage repair and YAP activity. Ku70, a key component of the nonhomologous end joining pathway to repair DNA damage, engaged in a dynamic competition with TEAD4 for binding to YAP, limiting the transcriptional activity of YAP. Depletion of Ku70 enhanced interaction between YAP and TEAD4 and boosted YAP transcriptional capacity. Consequently, Ku70 loss enhanced tumorigenesis in colon cancer and hepatocellular carcinoma (HCC) in vivo. YAP impeded DNA damage repair and elevated genome instability by inducing PARP1 degradation through the SMURF2-mediated ubiquitin-proteasome pathway. Analysis of samples from patients with HCC substantiated the link between Ku70 expression, YAP activity, PARP1 levels, and genome instability. In conclusion, this research provides insight into the mechanistic interactions between YAP and key regulators of DNA damage repair, highlighting the role of a Ku70-YAP-PARP1 axis in preserving genome stability.Significance: Increased yes-associated protein transcriptional activity stimulated by loss of Ku70 induces PARP1 degradation by upregulating SMURF2 to inhibit DNA damage, driving genome instability and tumorigenesis.
- 11 June 2024
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 84  (17) , 2836-2855
Ku70 Binding to YAP Alters PARP1 Ubiquitination to Regulate Genome Stability and Tumorigenesis
Yes-associated protein (YAP) is a central player in cancer development, with functions extending beyond its recognized role in cell growth regulation. Recent work has identified a link between YAP/transcriptional coactivator with PDZ-binding motif (TAZ) and the DNA damage response. Here, we investigated the mechanistic underpinnings of the cross-talk between DNA damage repair and YAP activity. Ku70, a key component of the nonhomologous end joining pathway to repair DNA damage, engaged in a dynamic competition with TEAD4 for binding to YAP, limiting the transcriptional activity of YAP. Depletion of Ku70 enhanced interaction between YAP and TEAD4 and boosted YAP transcriptional capacity. Consequently, Ku70 loss enhanced tumorigenesis in colon cancer and hepatocellular carcinoma (HCC) in vivo. YAP impeded DNA damage repair and elevated genome instability by inducing PARP1 degradation through the SMURF2-mediated ubiquitin-proteasome pathway. Analysis of samples from patients with HCC substantiated the link between Ku70 expression, YAP activity, PARP1 levels, and genome instability. In conclusion, this research provides insight into the mechanistic interactions between YAP and key regulators of DNA damage repair, highlighting the role of a Ku70-YAP-PARP1 axis in preserving genome stability. Significance: Increased yes-associated protein transcriptional activity stimulated by loss of Ku70 induces PARP1 degradation by upregulating SMURF2 to inhibit DNA damage, driving genome instability and tumorigenesis.
- 11 June 2024
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 84  (17) , 2836-2855
Ku70 Binding to YAP Alters PARP1 Ubiquitination to Regulate Genome Stability and Tumorigenesis
Yes-associated protein (YAP) is a central player in cancer development, with functions extending beyond its recognized role in cell growth regulation. Recent work has identified a link between YAP/transcriptional coactivator with PDZ-binding motif (TAZ) and the DNA damage response. Here, we investigated the mechanistic underpinnings of the cross-talk between DNA damage repair and YAP activity. Ku70, a key component of the nonhomologous end joining pathway to repair DNA damage, engaged in a dynamic competition with TEAD4 for binding to YAP, limiting the transcriptional activity of YAP. Depletion of Ku70 enhanced interaction between YAP and TEAD4 and boosted YAP transcriptional capacity. Consequently, Ku70 loss enhanced tumorigenesis in colon cancer and hepatocellular carcinoma (HCC) in vivo. YAP impeded DNA damage repair and elevated genome instability by inducing PARP1 degradation through the SMURF2-mediated ubiquitin-proteasome pathway. Analysis of samples from patients with HCC substantiated the link between Ku70 expression, YAP activity, PARP1 levels, and genome instability. In conclusion, this research provides insight into the mechanistic interactions between YAP and key regulators of DNA damage repair, highlighting the role of a Ku70-YAP-PARP1 axis in preserving genome stability. Significance: Increased yes-associated protein transcriptional activity stimulated by loss of Ku70 induces PARP1 degradation by upregulating SMURF2 to inhibit DNA damage, driving genome instability and tumorigenesis.
- Open Access
- 23 June 2023
- Published by Springer Nature in Nature Communications
- Vol. 14  (1) , 1-16
The role of mechano-regulated YAP/TAZ in erectile dysfunction
Phosphodiesterase type 5 inhibitors (PDE5is) constitute the primary therapeutic option for treating erectile dysfunction (ED). Nevertheless, a substantial proportion of patients, approximately 30%, do not respond to PDE5i treatment. Therefore, new treatment methods are needed. In this study, we identified a pathway that contributes to male erectile function. We show that mechano-regulated YAP/TAZ signaling in smooth muscle cells (SMCs) upregulates adrenomedullin transcription, which relaxed the SMCs to maintain erection. Using single-nucleus RNA sequencing, we investigated how penile erection stretches the SMCs, inducing YAP/TAZ activity. Subsequently, we demonstrate that YAP/TAZ plays a role in erectile function and penile rehabilitation, using genetic lesions and various animal models. This mechanism relies on direct transcriptional regulation of adrenomedullin by YAP/TAZ, which in turn modulates penile smooth muscle contraction. Importantly, conventional PDE5i, which targets NO-cGMP signaling, does not promote erectile function in YAP/TAZ-deficient ED model mice. In contrast, by activating the YAP/TAZ-adrenomedullin cascade, mechanostimulation improves erectile function in PDE5i nonrespondent ED model rats and mice. Furthermore, using clinical retrospective observational data, we found that mechanostimulation significantly promotes erectile function in patients irrespective of PDE5i use. Our studies lay the groundwork for exploring the mechano-YAP/TAZ-adrenomedullin axis as a potential target in the treatment of ED.
- 23 June 2023
- Published by Springer Nature in Nature Communications
- Vol. 14  (1) , 1-16
Open AccessThe role of mechano-regulated YAP/TAZ in erectile dysfunction
Phosphodiesterase type 5 inhibitors (PDE5is) constitute the primary therapeutic option for treating erectile dysfunction (ED). Nevertheless, a substantial proportion of patients, approximately 30%, do not respond to PDE5i treatment. Therefore, new treatment methods are needed. In this study, we identified a pathway that contributes to male erectile function. We show that mechano-regulated YAP/TAZ signaling in smooth muscle cells (SMCs) upregulates adrenomedullin transcription, which relaxed the SMCs to maintain erection. Using single-nucleus RNA sequencing, we investigated how penile erection stretches the SMCs, inducing YAP/TAZ activity. Subsequently, we demonstrate that YAP/TAZ plays a role in erectile function and penile rehabilitation, using genetic lesions and various animal models. This mechanism relies on direct transcriptional regulation of adrenomedullin by YAP/TAZ, which in turn modulates penile smooth muscle contraction. Importantly, conventional PDE5i, which targets NO-cGMP signaling, does not promote erectile function in YAP/TAZ-deficient ED model mice. In contrast, by activating the YAP/TAZ-adrenomedullin cascade, mechanostimulation improves erectile function in PDE5i nonrespondent ED model rats and mice. Furthermore, using clinical retrospective observational data, we found that mechanostimulation significantly promotes erectile function in patients irrespective of PDE5i use. Our studies lay the groundwork for exploring the mechano-YAP/TAZ-adrenomedullin axis as a potential target in the treatment of ED.